176 related articles for article (PubMed ID: 21247538)
1. Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial).
Applegate RJ; Yaqub M; Hermiller JB; Sood P; Yu S; Doostzadeh J; Williams JE; Farhat N; Caputo R; Lansky AJ; Cutlip DE; Sudhir K; Stone GW
Am J Cardiol; 2011 Mar; 107(6):833-40. PubMed ID: 21247538
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
3. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
[TBL] [Abstract][Full Text] [Related]
4. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
5. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
7. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545
[TBL] [Abstract][Full Text] [Related]
8. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716
[TBL] [Abstract][Full Text] [Related]
9. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
[TBL] [Abstract][Full Text] [Related]
10. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous coronary intervention with second-generation paclitaxel-eluting stents versus everolimus-eluting stents in United States contemporary practice (REWARDS TLX Trial).
Waksman R; Ghali M; Goodroe R; Ryan T; Turco M; Ring M; McGarry T; Dobies D; Shammas N; Steinberg DH; Swymelar S; Kaneshige K; Torguson R
Am J Cardiol; 2012 Oct; 110(8):1119-24. PubMed ID: 22762711
[TBL] [Abstract][Full Text] [Related]
12. An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III trials.
Bartorelli AL; Serruys PW; Miquel-Hébert K; Yu S; Pierson W; Stone GW;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):60-6. PubMed ID: 20578194
[TBL] [Abstract][Full Text] [Related]
13. Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial.
Hermiller JB; Fergus T; Pierson W; Su X; Sood P; Sudhir K; Stone GW
Am Heart J; 2009 Dec; 158(6):1005-10. PubMed ID: 19958868
[TBL] [Abstract][Full Text] [Related]
14. Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry.
Gordon PC; Applegate RJ; Hermiller JB; Weinsier SB; Doostzadeh J; Cao S; Sudhir K; Lansky AJ; Stone GW
Catheter Cardiovasc Interv; 2010 Feb; 75(2):179-86. PubMed ID: 19877267
[TBL] [Abstract][Full Text] [Related]
15. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial.
Brener SJ; Kereiakes DJ; Simonton CA; Rizvi A; Newman W; Mastali K; Wang JC; Caputo R; Smith RS; Ying SW; Cutlip DE; Stone GW
Am Heart J; 2013 Dec; 166(6):1035-42. PubMed ID: 24268218
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
Simsek C; Räber L; Magro M; Boersma E; Onuma Y; Stefanini GG; Zanchin T; Kalesan B; Wenaweser P; Jüni P; van Geuns RJ; van Domburg RT; Windecker S; Serruys PW
Int J Cardiol; 2013 Dec; 170(1):36-42. PubMed ID: 24196314
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial.
Applegate R; Hermiller J; Williams J; Gordon P; Doostzadeh J; Cao S; Su X; Sudhir K; Lansky A; Simonton C; Stone G
Catheter Cardiovasc Interv; 2010 Nov; 76(5):644-51. PubMed ID: 20506356
[TBL] [Abstract][Full Text] [Related]
18. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial.
Claessen BE; Beijk MA; Legrand V; Ruzyllo W; Manari A; Varenne O; Suttorp MJ; Tijssen JG; Miquel-Hebert K; Veldhof S; Henriques JP; Serruys PW; Piek JJ
Circ Cardiovasc Interv; 2009 Aug; 2(4):339-47. PubMed ID: 20031737
[TBL] [Abstract][Full Text] [Related]
19. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Mahaffey KW; Cutlip DE; Fitzgerald PJ; Sood P; Su X; Lansky AJ;
JAMA; 2008 Apr; 299(16):1903-13. PubMed ID: 18430909
[TBL] [Abstract][Full Text] [Related]
20. Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV clinical trials.
Ito H; Hermiller JB; Yaqub M; Newman W; Sood P; Wang JC; Cannon L; Maddux JE; Sudhir K; Stone GW
J Interv Cardiol; 2011 Dec; 24(6):505-13. PubMed ID: 21919955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
